Literature DB >> 20482510

Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy.

Falk Kiefer1, Karl Mann.   

Abstract

By updating John Littleton's work published 15 years ago this review summarizes recent work on pharmacodynamic aspects of acamprosate and the perspective for future developments. In addition to insights into the role of glutamatergic receptor systems, craving and relapse inspired by acamprosate, clinical research points towards one question: if we knew how acamprosate works, we might also be able to generate hypotheses, for whom it does work. Recent research on acamprosate tightly links pre-clinical and clinical research that includes molecular biology, animal models, pharmacogenetic and imaging genetic trials, and clinical efficacy studies. To increase the efficacy of this drug, targeted treatment and individualized therapy approaches seem useful and necessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482510     DOI: 10.2174/138161210791516341

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

Review 1.  Neurochemical and neurostructural plasticity in alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  ACS Chem Neurosci       Date:  2012-04-16       Impact factor: 4.418

Review 2.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

3.  Acamprosate: an alcoholism treatment that may not be what we thought.

Authors:  Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2014-03       Impact factor: 7.853

4.  [Pharmacological prophylactic treatment for relapse of alcohol dependence : Results of current meta-analyses].

Authors:  J Mutschler; M Soyka
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

5.  High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.

Authors:  John C Crabbe; Angela R Ozburn; Pamela Metten; Amanda Barkley-Levenson; Jason P Schlumbohm; Stephanie E Spence; Wyatt R Hack; Lawrence C Huang
Journal:  Pharmacol Biochem Behav       Date:  2017-08-05       Impact factor: 3.533

6.  Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1.

Authors:  Moonnoh R Lee; David J Hinton; Jinhua Wu; Prasanna K Mishra; John D Port; Slobodan I Macura; Doo-Sup Choi
Journal:  Neurosci Lett       Date:  2010-12-21       Impact factor: 3.046

7.  Calcium chloride mimics the effects of acamprosate on cognitive deficits in chronic alcohol-exposed mice.

Authors:  Grishma Pradhan; Patrick R Melugin; Fei Wu; Hannah M Fang; Rachel Weber; Sven Kroener
Journal:  Psychopharmacology (Berl)       Date:  2018-04-20       Impact factor: 4.530

Review 8.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

Review 9.  Treatment of the psychiatric problems associated with fragile X syndrome.

Authors:  Randi J Hagerman; Jonathan Polussa
Journal:  Curr Opin Psychiatry       Date:  2015-03       Impact factor: 4.741

Review 10.  Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.

Authors:  Dejan B Budimirovic; Elizabeth Berry-Kravis; Craig A Erickson; Scott S Hall; David Hessl; Allan L Reiss; Margaret K King; Leonard Abbeduto; Walter E Kaufmann
Journal:  J Neurodev Disord       Date:  2017-06-12       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.